Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Briel

Showing results (241-250 of 288) with videos related to

Pageof 29
Sort By:
Trials|November 11, 2009
Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trialsXin Sun, Matthias Briel, Jason W Busse, et al.
BMJ (Clinical Research Ed.)|March 30, 2011
The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic reviewXin Sun, Matthias Briel, Jason W Busse, et al.
Journal of Clinical Epidemiology|May 14, 2017
GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklistElie A Akl, Vivian Welch, Kevin Pottie, et al.
Journal of Clinical Epidemiology|May 11, 2025
Meta-research on patient-reported outcomes in trial protocols and results publications suggested large outcome reporting biasAla Taji Heravi, Dmitry Gryaznov, Jason W Busse, et al.
JAMA|November 3, 2005
Randomized trials stopped early for benefit: a systematic reviewVictor M Montori, P J Devereaux, Neill K J Adhikari, et al.
Journal of Clinical Epidemiology|April 17, 2017
GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationaleVivian A Welch, Elie A Akl, Gordon Guyatt, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 11, 2021
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group, Alpha Diallo, Marius Trøseid, et al.
Open Forum Infectious Diseases|April 10, 2023
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Alexandra Griessbach, Frédérique Chammartin, Irene A Abela, et al.
JAMA Network Open|September 3, 2025
Nonregistration, Discontinuation, and Nonpublication of Randomized Trials: A Systematic ReviewBenjamin Speich, Ala Taji Heravi, Christof M Schönenberger, et al.
Plos One|January 24, 2025
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune functionAnnette Audigé, Alain Amstutz, Macé M Schuurmans, et al.
Pageof 29

Showing results (241-250 of 288) with videos related to

Sort By:
Pageof 29
Trials|November 11, 2009
Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trialsXin Sun, Matthias Briel, Jason W Busse, et al.
BMJ (Clinical Research Ed.)|March 30, 2011
The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic reviewXin Sun, Matthias Briel, Jason W Busse, et al.
Journal of Clinical Epidemiology|May 14, 2017
GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklistElie A Akl, Vivian Welch, Kevin Pottie, et al.
Journal of Clinical Epidemiology|May 11, 2025
Meta-research on patient-reported outcomes in trial protocols and results publications suggested large outcome reporting biasAla Taji Heravi, Dmitry Gryaznov, Jason W Busse, et al.
JAMA|November 3, 2005
Randomized trials stopped early for benefit: a systematic reviewVictor M Montori, P J Devereaux, Neill K J Adhikari, et al.
Journal of Clinical Epidemiology|April 17, 2017
GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationaleVivian A Welch, Elie A Akl, Gordon Guyatt, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 11, 2021
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group, Alpha Diallo, Marius Trøseid, et al.
Open Forum Infectious Diseases|April 10, 2023
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Alexandra Griessbach, Frédérique Chammartin, Irene A Abela, et al.
JAMA Network Open|September 3, 2025
Nonregistration, Discontinuation, and Nonpublication of Randomized Trials: A Systematic ReviewBenjamin Speich, Ala Taji Heravi, Christof M Schönenberger, et al.
Plos One|January 24, 2025
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune functionAnnette Audigé, Alain Amstutz, Macé M Schuurmans, et al.
Pageof 29